Stocktoria
Fortrea Holdings Inc. FTRE
Fortrea Holdings Inc. (FTRE) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.7B at a -36.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.006 |
| Retained earnings / assets | -0.509 |
| EBIT / assets | -0.321 |
| Equity / liabilities | 0.262 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FTRE | Fortrea Holdings Inc. | 3/9 | -3.58 | — | +1% |
| NTRA | Natera, Inc. | 3/9 | 0.87 | — | +35.9% |
| RDNT | RadNet, Inc. | 3/9 | 1.4 | — | +11.5% |
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
FAQ
Is FTRE financially healthy?
Fortrea Holdings Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does FTRE pay a dividend?
No, Fortrea Holdings Inc. does not currently pay a dividend.
How profitable is FTRE?
In FY2025, Fortrea Holdings Inc. had a net margin of -36.2% and a return on equity of -175.0%.
What is the analyst price target for FTRE?
The average Wall-Street price target for Fortrea Holdings Inc. is $16.39, about 10.6% below the recent price, from 11 analysts (consensus: buy).
Is FTRE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Fortrea Holdings Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.